Vaxart Inc (VXRT)
0.7289
-0.02
(-2.68%)
USD |
NASDAQ |
May 03, 16:00
0.7419
+0.01
(+1.78%)
After-Hours: 20:00
Vaxart Cash from Financing (Quarterly): -0.066M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.066M |
| September 30, 2023 | -0.008M |
| June 30, 2023 | 13.90M |
| March 31, 2023 | 1.42M |
| December 31, 2022 | 8.596M |
| September 30, 2022 | 4.988M |
| June 30, 2022 | 2.838M |
| March 31, 2022 | 1.04M |
| December 31, 2021 | 0.505M |
| September 30, 2021 | 20.64M |
| June 30, 2021 | 37.06M |
| March 31, 2021 | 67.59M |
| December 31, 2020 | 5.10M |
| September 30, 2020 | 98.61M |
| June 30, 2020 | 15.06M |
| March 31, 2020 | 19.54M |
| December 31, 2019 | -2.228M |
| September 30, 2019 | 7.755M |
| June 30, 2019 | 8.31M |
| March 31, 2019 | 2.123M |
| December 31, 2018 | -0.519M |
| September 30, 2018 | -0.468M |
| June 30, 2018 | -0.477M |
| March 31, 2018 | -0.265M |
| December 31, 2017 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2017 | |
| June 30, 2017 | -0.20M |
| March 31, 2017 | -0.10M |
| December 31, 2016 | -0.10M |
| September 30, 2016 | |
| June 30, 2016 | 18.00M |
| March 31, 2016 | -0.10M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | -0.10M |
| June 30, 2015 | -0.10M |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 26.80M |
| December 31, 2013 | |
| September 30, 2013 | |
| September 30, 2012 | -24.48M |
| June 30, 2012 | 0.00 |
| March 31, 2012 | 0.00 |
| December 31, 2011 | 0.017M |
| September 30, 2011 | 0.121M |
| June 30, 2011 | 0.23M |
| March 31, 2011 | 0.295M |
| December 31, 2010 | 0.227M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.228M
Minimum
Dec 2019
98.61M
Maximum
Sep 2020
16.35M
Average
7.755M
Median
Sep 2019
Cash from Financing (Quarterly) Benchmarks
| Novavax Inc | 100.39M |
| aTyr Pharma Inc | 6.034M |
| Allogene Therapeutics Inc | 0.155M |
| AIM ImmunoTech Inc | 0.147M |
| Protalix BioTherapeutics Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -13.52M |
| Cash from Investing (Quarterly) | 15.10M |
| Free Cash Flow | -72.32M |
| Free Cash Flow Per Share (Quarterly) | -0.0946 |
| Free Cash Flow to Equity (Quarterly) | -13.42M |
| Free Cash Flow to Firm (Quarterly) | -13.12M |
| Free Cash Flow Yield | -69.79% |